Iovance Bio's mid-stage study of LN-144 in melanoma underway [Seeking Alpha]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Seeking Alpha
Iovance Bio's mid-stage study of LN-144 in melanoma underwayThe first patient has beendosed in a Phase 2 clinical trial,C-144-01, assessing Iovance Biotherapeutics' (IOVA-3.2%) lead candidate LN-144 (lifileucel) in metastatic melanoma patients. The primary endpoint of the 85-subject study is objective response rate (ORR) at month 6.According to ClinicalTrials.gov, the estimated primary completion date is March 2019.LN-144 is a cell therapy, specifically, autologous tumor infiltrating lymphocytes extracted from the patient, expanded in the laboratory and then reinfused where they attack and kill cancer cells.Click to subscribe to real-time analytics on IOVANow read:Your Daily Pharma Scoop: Iovance Zooms Ahead, Palatin Surges And Deciphera Moves Up »
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Market Sentiment Around Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results [Seeking Alpha]Seeking Alpha
- Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why [Yahoo! Finance]Yahoo! Finance
- Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 2/28/24 - Miss
IOVA
Sec Filings
- 4/3/24 - Form 8-K
- 3/29/24 - Form 8-K
- 3/19/24 - Form SC
- IOVA's page on the SEC website